RedHill Biopharma Ltd. (RDHL)
4.88
-0.14 (-2.79%)
At close: Feb 20, 2025, 3:57 PM
4.90
0.41%
After-hours: Feb 20, 2025, 03:58 PM EST
undefined% (undefined)
| Bid | 4.7 |
| Market Cap | 6.22M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -302.63 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 4.98 |
| Volume | 6,722 |
| Avg. Volume (20D) | 14,971 |
| Open | 4.99 |
| Previous Close | 5.02 |
| Day's Range | 4.87 - 4.99 |
| 52-Week Range | 4.87 - 20.27 |
| Beta | undefined |
About RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development pr...
Sector Healthcare
IPO Date Jan 7, 2013
Employees 53
Stock Exchange NASDAQ
Ticker Symbol RDHL
Website https://www.redhillbio.com
6 months ago
+25.06%
Redhill Biopharma shares are trading higher after ...
Unlock content with
Pro Subscription
6 months ago
+10.76%
Redhill Biopharma shares are trading higher after the company announced results from multiple in vivo studies.
